Clinical Trial Update: ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis [Phase 3]

View source ↗

Summary

Phase 3 trial ARTEMIS-PH studying ambrisentan for pulmonary hypertension associated with idiopathic pulmonary fibrosis was terminated; results were posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Pulmonary Hypertension

Drugs mentioned

• LETAIRIS (ambrisentan)

Snippet

Sponsor: Gilead Sciences | Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension | Phase 3 | Status: TERMINATED | Results posted: 2014-04-22